Howard I. Scher

1.4k total papers · 131.3k total citations
803 papers, 63.3k citations indexed

About

Howard I. Scher is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Howard I. Scher has authored 803 papers receiving a total of 63.3k indexed citations (citations by other indexed papers that have themselves been cited), including 572 papers in Pulmonary and Respiratory Medicine, 308 papers in Oncology and 244 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Howard I. Scher's work include Prostate Cancer Treatment and Research (528 papers), Radiopharmaceutical Chemistry and Applications (221 papers) and Prostate Cancer Diagnosis and Treatment (100 papers). Howard I. Scher is often cited by papers focused on Prostate Cancer Treatment and Research (528 papers), Radiopharmaceutical Chemistry and Applications (221 papers) and Prostate Cancer Diagnosis and Treatment (100 papers). Howard I. Scher collaborates with scholars based in United States, United Kingdom and France. Howard I. Scher's co-authors include Charles L. Sawyers, Johann S. de Bono, Michael J. Morris, William Kevin Kelly, Cora N. Sternberg, Glenn Heller, Carlos Cordon‐Cardo, Martin Fleisher, Steven M. Larson and Daniel C. Danila and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Howard I. Scher

781 papers receiving 61.7k citations

Hit Papers

Increased Survival with E... 1985 2026 1998 2012 2012 2008 2008 2009 2015 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
    2012 3.3k citations Howard I. Scher, Karim Fizazi et al. New England Journal of Medicine profile →
  2. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
    2008 1.7k citations Johann S. de Bono, Howard I. Scher et al. Clinical Cancer Research profile →
  3. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
    2008 1.7k citations Howard I. Scher, Susan Halabi et al. Journal of Clinical Oncology profile →
  4. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
    2009 1.7k citations Nicola J. Clegg, Yu Chen et al. profile →
  5. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
    2015 1.6k citations Ethan Basch, Mark G. Kris et al. Journal of Clinical Oncology profile →
  6. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
    2005 1.5k citations Zhenbang Chen, Lloyd C. Trotman et al. Nature profile →
  7. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress
    1994 1.3k citations Russell K. Portenoy, Howard T. Thaler et al. European Journal of Cancer profile →
  8. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    2012 1.0k citations Karim Fizazi, Howard I. Scher et al. The Lancet Oncology profile →
  9. Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
    2011 885 citations Brett S. Carver, John Wongvipat et al. Cancer Cell profile →
  10. Rapid screening for psychologic distress in men with prostate carcinoma
    1998 872 citations Andrew Roth, Alice B. Kornblith et al. Cancer profile →
  11. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
    2010 807 citations Howard I. Scher, Tomasz M. Beer et al. The Lancet profile →
  12. Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
    2005 797 citations Howard I. Scher, Charles L. Sawyers Journal of Clinical Oncology profile →
  13. Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
    1988 763 citations Janice Gabrilove, Ann A. Jakubowski et al. New England Journal of Medicine profile →
  14. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer
    2005 739 citations William Kevin Kelly, Owen A. O’Connor et al. Journal of Clinical Oncology profile →
  15. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    2000 665 citations Francis M. Sirotnak, V.A. Miller et al. PubMed profile →
  16. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
    1989 539 citations Cora N. Sternberg, Alan Yagoda et al. Cancer profile →
  17. Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy
    1999 537 citations Dean F. Bajorin, Paul M. Dodd et al. Journal of Clinical Oncology profile →
  18. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
    2003 524 citations Wm. Kevin Kelly, Victoria M. Richon et al. PubMed profile →
  19. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    2000 521 citations Lisa M. Butler, David B. Agus et al. PubMed profile →
  20. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
    2007 520 citations Daniel C. Danila, Glenn Heller et al. Clinical Cancer Research profile →
  21. Symptom prevalence, characteristics and distress in a cancer population
    1994 515 citations Russell K. Portenoy, Howard T. Thaler et al. Quality of Life Research profile →
  22. Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium
    1985 513 citations Cora N. Sternberg, Alan Yagoda et al. The Journal of Urology profile →
  23. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
    2005 497 citations Gary J. Kelloff, Howard I. Scher et al. Clinical Cancer Research profile →
  24. M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium
    1988 492 citations Cora N. Sternberg, Alan Yagoda et al. The Journal of Urology profile →
  25. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
    2016 458 citations Howard I. Scher, David Lu et al. profile →
  26. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    2013 434 citations Susan F. Slovin, Celestia S. Higano et al. Annals of Oncology profile →
  27. Clinical implications of PTEN loss in prostate cancer
    2018 421 citations Tamara Jamaspishvili, David M. Berman et al. Nature Reviews Urology profile →
  28. High-risk prostate cancer—classification and therapy
    2014 335 citations Albert J. Chang, Karen A. Autio et al. Nature Reviews Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Howard I. Scher 34.1k 22.7k 18.2k 13.7k 10.4k 803 63.3k
Johann S. de Bono 28.8k 0.8× 22.2k 1.0× 18.9k 1.0× 14.1k 1.0× 9.8k 0.9× 1.0k 52.9k
Philip W. Kantoff 22.7k 0.7× 12.2k 0.5× 16.9k 0.9× 8.3k 0.6× 4.9k 0.5× 617 48.0k
Eric J. Small 24.2k 0.7× 14.3k 0.6× 8.9k 0.5× 8.3k 0.6× 6.7k 0.6× 612 35.7k
Fred Saad 23.7k 0.7× 15.3k 0.7× 7.6k 0.4× 6.9k 0.5× 8.6k 0.8× 1.2k 36.4k
Nicholas J. Vogelzang 22.6k 0.7× 17.2k 0.8× 8.3k 0.5× 6.4k 0.5× 5.5k 0.5× 701 41.7k
W. Marston Linehan 21.6k 0.6× 7.6k 0.3× 22.9k 1.3× 13.4k 1.0× 2.9k 0.3× 586 45.7k
Mithat Gönen 19.3k 0.6× 26.4k 1.2× 8.0k 0.4× 5.8k 0.4× 8.5k 0.8× 780 60.4k
Kenneth J. Pienta 17.5k 0.5× 17.9k 0.8× 21.8k 1.2× 12.1k 0.9× 4.4k 0.4× 672 49.6k
Ian F. Tannock 16.7k 0.5× 16.5k 0.7× 9.6k 0.5× 8.1k 0.6× 5.2k 0.5× 426 44.0k
Seth M. Steinberg 13.5k 0.4× 29.0k 1.3× 15.6k 0.9× 7.9k 0.6× 3.2k 0.3× 863 58.7k

Countries citing papers authored by Howard I. Scher

Since Specialization
Citations

This map shows the geographic impact of Howard I. Scher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard I. Scher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard I. Scher more than expected).

Fields of papers citing papers by Howard I. Scher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard I. Scher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard I. Scher. The network helps show where Howard I. Scher may publish in the future.

Co-authorship network of co-authors of Howard I. Scher

This figure shows the co-authorship network connecting the top 25 collaborators of Howard I. Scher. A scholar is included among the top collaborators of Howard I. Scher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard I. Scher. Howard I. Scher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevin C. Jones Breakdown of academic impact, for papers by Shlomo Havlin Breakdown of academic impact, for papers by Willy Verstraete Breakdown of academic impact, for papers by Liqiang Mai Breakdown of academic impact, for papers by Janusz Pawliszyn Breakdown of academic impact, for papers by Charles F. Reynolds Breakdown of academic impact, for papers by Bernard Moss Breakdown of academic impact, for papers by Mitchel S. Berger
Rankless by CCL
2026